90 filings
6-K
ADXN
Addex Therapeutics Ltd
29 Apr 24
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
6:05am
6-K
ADXN
Addex Therapeutics Ltd
18 Apr 24
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
6:05am
6-K
ADXN
Addex Therapeutics Ltd
3 Apr 24
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
6:05am
6-K
ADXN
Addex Therapeutics Ltd
30 Jan 24
Current report (foreign)
4:58pm
6-K/A
ADXN
Addex Therapeutics Ltd
21 Dec 23
Current report (foreign) (amended)
6:00am
6-K
lyyuxdcfo2a
20 Dec 23
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
6:05am
6-K
efk92yj
14 Dec 23
Addex Creates Treasury Shares
6:05am
6-K
ng69vvz3
29 Nov 23
Current report (foreign)
6:00am
6-K
ajurl9l
28 Nov 23
Addex Convenes Extraordinary General Meeting
6:05am
6-K
z0l t4lo7
14 Nov 23
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
6:05am
6-K
q8qctzgo
8 Nov 23
Current report (foreign)
6:05am
6-K
9mce1
20 Oct 23
Addex Completes ADS Ratio Change
6:05am
6-K
web277twjnz 3z
6 Oct 23
Addex Announces Plan to Implement ADS Ratio Change
4:00pm
6-K
7gxpm 9vdd7
20 Sep 23
Addex mGlu2 NAM Cognition Program Receives €4 Million Grant
6:05am
6-K
ukw4hj h4
5 Sep 23
Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
6:10am
6-K
gttx5rlgsv
5 Sep 23
Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain
6:10am
6-K
ggits7fxx hzjum
10 Aug 23
Current report (foreign)
6:31am
6-K
5ywto 59bqv21as
3 Aug 23
Current report (foreign)
6:05am
6-K
pgxnz h96
24 Jul 23
Current report (foreign)
6:05am
6-K
qqwse7
15 Jun 23
Addex Increases Issued Share Capital to Create Treasury Shares
6:05am